GLP-1 Drugs Protect the Heart During Heart Attacks in Rats With Metabolic Syndrome
Dulaglutide improved heart function more than exenatide in rats with metabolic syndrome, both protecting against heart attack damage through antioxidant mechanisms.
Quick Facts
What This Study Found
After 6 weeks of treatment in rats with metabolic syndrome:
- Exenatide improved ejection fraction by 3% vs untreated MetS group
- Dulaglutide improved ejection fraction by 7% vs untreated MetS group
- Histology showed reduced cardiomyocyte cross-sectional area: 11% reduction with exenatide, 18% with dulaglutide
- Both drugs reduced oxidative stress biomarkers
- Dulaglutide showed a slight advantage overall
Key Numbers
- 24 rats in 3 groups (8 per group)
- Exenatide dose: 5 μg/kg
- Dulaglutide dose: 0.6 mg/kg
- Treatment duration: 6 weeks
- Ejection fraction improvement: 3% (exenatide), 7% (dulaglutide)
- Cardiomyocyte area reduction: 11% (exenatide), 18% (dulaglutide)
How They Did This
24 Wistar albino rats were given metabolic syndrome through diet. They were divided into three groups: untreated MetS, exenatide-treated (5 μg/kg), and dulaglutide-treated (0.6 mg/kg). After 6 weeks, heart function was assessed by echocardiography in living animals. Hearts were then removed and subjected to simulated ischemia-reperfusion injury using a Langendorff apparatus. Tissue was analyzed histologically and for oxidative stress biomarkers.
Why This Research Matters
People with metabolic syndrome have higher risk of heart attacks and worse outcomes when they occur. GLP-1 drugs are prescribed for diabetes and weight loss in this population. Evidence that they also protect the heart during a heart attack would be a major additional benefit. This animal study provides mechanistic support for the cardiovascular benefits seen in human clinical trials.
The Bigger Picture
People with metabolic syndrome have higher heart attack risk and worse outcomes. GLP-1 drugs are prescribed for diabetes and weight loss in this population. Evidence of additional heart protection supports their use.
What This Study Doesn't Tell Us
Tested in rats with diet-induced metabolic syndrome, not humans. The simulated heart attack (Langendorff) is a simplified model. The MetS model may not replicate all features of human metabolic syndrome. Only 8 rats per group limits statistical power. The treatment was given before the heart attack (pretreatment), not after. The 6-week duration may not capture long-term effects.
Questions This Raises
- ?Why did dulaglutide outperform exenatide?
- ?Would semaglutide or tirzepatide show even stronger cardioprotection?
Trust & Context
- Key Stat:
- 7% ejection fraction improvement Dulaglutide improved heart ejection fraction by 7 percentage points in rats with metabolic syndrome, more than double exenatide's 3% improvement
- Evidence Grade:
- Rated preliminary: small animal study (24 rats) using a simplified heart attack model. Results need validation in larger animal studies and humans.
- Study Age:
- Published in 2024. Adds to preclinical evidence for GLP-1 cardioprotection that complements large human cardiovascular outcome trials.
- Original Title:
- Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 17(4) (2024)
- Authors:
- Ravic, Marko, Srejovic, Ivan, Novakovic, Jovana, Andjic, Marijana, Sretenovic, Jasmina, Muric, Maja, Nikolic, Marina, Bolevich, Sergey, Alekseevich Kasabov, Kirill, Petrovich Fisenko, Vladimir, Stojanovic, Aleksandra, Jakovljevic, Vladimir
- Database ID:
- RPEP-09128
Evidence Hierarchy
Frequently Asked Questions
Do GLP-1 drugs protect the heart during heart attacks?
In rats, both exenatide and dulaglutide reduced heart damage during simulated heart attacks, with dulaglutide showing stronger effects.
How do GLP-1 drugs protect the heart?
Partly through antioxidant mechanisms — they reduce oxidative stress in heart tissue, which is a major cause of damage during heart attacks.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09128APA
Ravic, Marko; Srejovic, Ivan; Novakovic, Jovana; Andjic, Marijana; Sretenovic, Jasmina; Muric, Maja; Nikolic, Marina; Bolevich, Sergey; Alekseevich Kasabov, Kirill; Petrovich Fisenko, Vladimir; Stojanovic, Aleksandra; Jakovljevic, Vladimir. (2024). Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.. Pharmaceuticals (Basel, Switzerland), 17(4). https://doi.org/10.3390/ph17040525
MLA
Ravic, Marko, et al. "Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Injury in Rats with Metabolic Syndrome.." Pharmaceuticals (Basel, 2024. https://doi.org/10.3390/ph17040525
RethinkPeptides
RethinkPeptides Research Database. "Effect of GLP-1 Receptor Agonist on Ischemia Reperfusion Inj..." RPEP-09128. Retrieved from https://rethinkpeptides.com/research/ravic-2024-effect-of-glp1-receptor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.